Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization (IS) (2016 - 2026)

Ani Pharmaceuticals' Depreciation & Amortization (IS) history spans 16 years, with the latest figure at $22.6 million for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (IS) changed 0.06% to $22.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $91.4 million, a 34.97% increase, with the full-year FY2025 number at $91.4 million, up 34.97% from a year prior.
  • Depreciation & Amortization (IS) hit $22.6 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $22.6 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (IS) for ANIP hit a ceiling of $23.3 million in Q2 2025 and a floor of $10.9 million in Q1 2021.
  • Historically, Depreciation & Amortization (IS) has averaged $16.2 million across 5 years, with a median of $14.7 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (IS): fell 2.55% in 2021 and later soared 58.41% in 2025.
  • Tracing ANIP's Depreciation & Amortization (IS) over 5 years: stood at $13.7 million in 2021, then increased by 5.85% to $14.5 million in 2022, then grew by 4.9% to $15.2 million in 2023, then soared by 48.74% to $22.6 million in 2024, then rose by 0.06% to $22.6 million in 2025.
  • Business Quant data shows Depreciation & Amortization (IS) for ANIP at $22.6 million in Q4 2025, $22.6 million in Q3 2025, and $23.3 million in Q2 2025.